ArticleClinical biochemistry2013
Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.
Article in Clinical biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 103 citations in OpenAlex.
- Solvent Interaction Analysis: A New Lens for Protein Structure and Diagnostics.International journal of molecular sciences · 2026Review
- Recruitment of apolipoprotein E facilitates Herpes simplex virus 1 attachment and release.Npj viruses · 2025Article
- Article
- Candidate High-Resolution Mass Spectrometry-Based Reference Method for the Quantification of Procalcitonin in Human Serum Using a Characterized Recombinant Protein as a Primary Calibrator.Analytical chemistry · 2022Article
- Proteomes Are of Proteoforms: Embracing the Complexity.Proteomes · 2021Review
- Development of an antibody-free ID-LC MS method for the quantification of procalcitonin in human serum at sub-microgram per liter level using a peptide-based calibration.Analytical and bioanalytical chemistry · 2021Article
- The Time Has Come for Quantitative Protein Mass Spectrometry Tests That Target Unmet Clinical Needs.Journal of the American Society for Mass Spectrometry · 2021Article
- Conjugating immunoassays to mass spectrometry: Solutions to contemporary challenges in clinical diagnostics.Trends in analytical chemistry : TRAC · 2020Review
- MALDI-TOF mass spectrometry-based quantification of C-peptide in diabetes patients.European journal of mass spectrometry (Chichester, England) · 2020Article
- Systematic assessment of antibody selectivity in plasma based on a resource of enrichment profiles.Scientific reports · 2019Article
- Isoform-Level Interpretation of High-Throughput Proteomics Data Enabled by Deep Integration with RNA-seq.Journal of proteome research · 2018Article
- Kinetics of plasma apolipoprotein E isoforms by LC-MS/MS: a pilot study.Journal of lipid research · 2018Article
- Needle lost in the haystack: multiple reaction monitoring fails to detectF1000Research · 2018Article
- Quantification by nano liquid chromatography parallel reaction monitoring mass spectrometry of human apolipoprotein A-I, apolipoprotein B, and hemoglobin A1c in dried blood spots.Proteomics. Clinical applications · 2017Article
- Review
- Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2016Review
- Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.Proteomes · 2016Review
- Personalized Proteomics: The Future of Precision Medicine.Proteomes · 2016Article
- Review
- Monolith immuno-affinity enrichment liquid chromatography tandem mass spectrometry for quantitative protein analysis of recombinant bovine somatotropin in serum.Analytical and bioanalytical chemistry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 5 countries.
Funding
Abstract
objectivesThe aim of this study was to develop high-throughput, quantitative and highly selective mass spectrometric, targeted immunoassays for clinically important proteins in human plasma or serum. DESIGN AND
methodsThe described method coupled mass spectrometric immunoassay (MSIA), a previously developed technique for immunoenrichment on a monolithic microcolumn activated with an anti-protein antibody and fixed in a pipette tip, to selected reaction monitoring (SRM) detection and accurate quantification of targeted peptides, including clinically relevant sequence or truncated variants.
resultsIn this report, we demonstrate the rapid development of MSIA-SRM assays for sixteen different target proteins spanning seven different clinically important areas (including neurological, Alzheimer's, cardiovascular, endocrine function, cancer and other diseases) and ranging in concentration from pg/mL to mg/mL. The reported MSIA-SRM assays demonstrated high sensitivity (within published clinical ranges), precision, robustness and high-throughput as well as specific detection of clinically relevant isoforms for many of the target proteins. Most of the assays were tested with bona-fide clinical samples. In addition, positive correlations, (R2 0.67-0.87, depending on the target peptide), were demonstrated for MSIA-SRM assay data with clinical analyzer measurements of parathyroid hormone (PTH) and insulin growth factor 1 (IGF1) in clinical sample cohorts.
conclusionsWe have presented a practical and scalable method for rapid development and deployment of MS-based SRM assays for clinically relevant proteins and measured levels of the target analytes in bona fide clinical samples. The method permits the specific quantification of individual protein isoforms and addresses the difficult problem of protein heterogeneity in clinical proteomics applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.